EFSA health claim opinion

EFSA rejects probiotic “heart cheese” health claim

By Shane Starling

- Last updated on GMT

EFSA rejects 38-publication strong dossier for probiotic heart health cheese
EFSA rejects 38-publication strong dossier for probiotic heart health cheese

Related tags Blood pressure

The European Food Safety Authority (EFSA) has rejected an article 13.5 claim that sought to link a probiotic cheese called Harmony with heart health benefits.

EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) found Estonian firm Piimandusühistu E-Piim’s dossier that contained 38 publications did not substantiate the proposed claim that read:

Regular consumption (at least 3 weeks) of 50 g/day Südamejuust (Heart cheese) of Harmony brand comprising probiotic Lactobacillus plantarum TENSIA helps to maintain the cardio-vascular system/heart health through reduction of blood pressure.”

The NDA said of four submitted, proprietary, unpublished intervention studies investigating the effects of the strain L. plantarum ​(Tensia) on blood pressure, three were uncontrolled and therefore not permissible as evidence.

The fourth was controlled – a randomised, double-blind, placebo-controlled, cross-over human intervention study – but the NDA said, “no significant differences in systolic or diastolic blood pressure changes were observed between the intervention and control groups during the study.”

It added: Post-hoc analyses were carried out by dividing the study population according to systolic blood pressure values at baseline. The Panel notes that these post-hoc analyses were not pre-planned and considers that no conclusions can be drawn from these analyses for the scientific substantiation of the claim.”

“In weighing the evidence, the Panel took into account that the only randomised, placebo-controlled human intervention study provided did not show an effect of consumption of L. plantarum TENSIAin Edam-type cheese on blood pressure.”

The 38 submitted publications included​guidelines, EFSA opinions, reports, narrative reviews, theses, human studies and ex vivo/in vitro ​mechanistic studies but the NDA said none of them, “addressed the effects of L. plantarum TENSIA”.

It also noted that in vitro ​information​about the functional properties of L. plantarum ​TENSIA (available in two patents) to produce angiotensin-converting enzyme (ACE) inhibitors via, “proteolytic activity in the cheese environment during maturation”​ did not, “predict an effect of L. plantarum TENSIAon blood pressure in vivo in humans.”

The NDA opinion can be found here.

Related news

Show more

Related products

show more

Sweetening solution for active nutrition

Sweetening solution for active nutrition

Content provided by ADM | 19-Feb-2024 | Case Study

When you add GrainSweet® Liquid Maltodextrin to your active nutrition applications, you get the production efficiencies, clean labels, and clean tastes...

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Related suppliers

Follow us


View more